FDG-PET comparative effectiveness data sought by AHCPR in technology review.
This article was originally published in The Gray Sheet
Executive Summary
FDG-PET MEDICARE TECHNOLOGY ASSESSMENT: AHCPR SEEKS SCIENTIFIC DATA on use of the imaging modality "as a diagnostic and man-agement tool for use in patients with focal or partial epilepsy" in an Aug. 14 Federal Register notice. The ongoing evaluation of fluorodeoxyglucose positron emission tomography imaging will form the basis of the Health Care Financing Administration's Medicare coverage decision on the technology.